Estimated use of abacavir among adults and children enrolled in public sector antiretroviral therapy programmes in Gauteng Province, South Africa by Evans, D et al.











Abacavir (ABC), a nucleoside reverse transcriptase inhibitor 
(NRTI), has been shown to be an effective component of 
combination antiretroviral therapy (ART) regimens for both 
paediatric and adult patients.1-3 South African (SA) national 
ART treatment guidelines recommend ABC for first- and 
second-line regimens in paediatric patients aged ≥3 months.4 
Despite demonstrating a durable antiretroviral response, ABC 
is not a preferred option for first- or second-line adult regimens 
in SA, primarily due to its relatively high cost, but also due to 
concerns about toxicity, particularly hypersensitive reactions, 
although these are only experienced in 4% of individuals 
receiving ABC.5-7 Such reactions commonly present as a rash 
and fever, but may manifest as fatigue, flu-like symptoms 
or gastrointestinal upset. Common adverse effects include 
headache, loss of appetite, nausea and diarrhoea.7 Of all 
nucleoside reverse transcriptase inhibitors (NRTIs), ABC is 
associated with the lowest rate of mitochondrial dysfunction, 
including lactic acidosis, peripheral neuropathy and lipo-
atrophy.5 Substitution of stavudine (d4T) with ABC improves 
mitochondrial indices, reduces adipocyte apoptosis,8 and has 
been shown to be superior to substitution with zidovudine 
(ZDV) in adults. In older children, once-daily use of ABC 
has also been shown to be effective, facilitating adherence and 
improving patient satisfaction.9-11 ABC-containing regimens 
are used in adult cases where standard first- and second-line 
treatments have either failed or cannot be tolerated.
Given current national guidelines for limited inclusion of 
ABC in highly active ART (HAART) regimens, use of the drug 
among HIV-positive adults eligible for treatment is generally 
expected to be low. In 2011, however, a higher than anticipated 
use of ABC was observed across all provinces of SA. Actual 
use outpaced the projected need for the drug, placing strains 
on supplies and programme budgets. In response to concerns 
about the unnecessary use of ABC (300 mg), we investigated 
current prescribing of the drug to adults and children accessing 
ART in public sector programmes across Gauteng Province.
Methods 
In 2011 we performed a cross-sectional study of 4 urban 
public sector antiretroviral clinics in Gauteng Province 
supported by Right to Care – a non-governmental organisation 
supporting ART rollout in SA with funding from the United 
States Agency for International Development (USAID)/
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adults and adolescents should include ABC as an alternative 
to standard first- or second-line ART.
S Afr J HIV Med 2012;13(3):134-137. DOI:10.719/SAJHIVMED.822
Estimated use of abacavir among adults 
and children enrolled in public sector 
antiretroviral therapy programmes in 
Gauteng Province, South Africa
Denise Evans, Mhairi Maskew, Cassidy Heneger, Ian Sanne
Health Economics and Epidemiology Research Office, Department of Internal Medicine, Faculty of Health Sciences, 
University of the Witwatersrand, Johannesburg
Denise Evans, PhD
Mhairi Maskew, MB BCh, MSc
Department of Epidemiology, Gillings School of Global Public Health, University of North Carolina at Chapel Hill, 
USA
Cassidy Heneger, PhD
Clinical HIV Research Unit, Department of Internal Medicine, Faculty of Health Sciences, University of the 
Witwatersrand, and Right to Care, Johannesburg
Ian Sanne, MB BCh, FCP (SA), FRCP (Lond)
Corresponding author: D Evans (devans@witshealth.co.za)







President’s Emergency Plan for AIDS Relief 
(PEPFAR).12 The clinics operate according to 
SA national ART guidelines and are run by 
the national Department of Health, as part of 
its development of accredited Comprehensive 
Care, Management and Treatment (CCMT) 
sites with doctor-managed initiation and 
follow-up.13,14 Age categories were defined 
according to the World Health Organization 
(WHO) for paediatrics (<10 years of age), 
adolescents (aged 10 - 18 years) and adults 
(aged >18 years).15 Medical records were 
reviewed for all patients actively receiving 
HAART at the Themba Lethu Clinic (TLC) 
in central Johannesburg (JHB) and at 3 other 
adjacent sites to the north, east and west of 
TLC. Data on current drug regimens, patient 
demographics and clinical characteristics were 
extracted from TherapyEdge-HIVTM (TE), an 
electronic patient management system used 
at the clinics. Use of TE data was approved 
by the Human Research Ethics Committee of 
the University of the Witwatersrand (HREC-
Medical M060626/M110140). 
Results
Of 23 084 patients, 76% (22 089) were adults 
and 5% (995) were children and adolescents 
(aged ≤18 years), reflecting that the HIV clinics 
were mainly adult-orientated. The majority of 
patients attending the central-JHB (12 120/12 
185; 99.5%), west-JHB (1 875/2 267; 82.7%) 
and east-JHB (2 705/2 773; 97.5%) clinics were 
adults aged >18 years. TLC had a small cohort 
of paediatric (<10 years) and adolescent (10 - 
18 years) patients (65/12 185; 0.5%), compared 
with north-JHB, where paediatric/adolescent 
(470/5 859; 8.0%) and adult HIV-positive 
patients (5 389/5 859; 92%) were seen separately 
(Table 1).
The total number of patients receiving ABC 
was 619/23 084 (2.7%). An estimated 0.9% 
(206/22 089) of adults attending the 4 sites 
were prescribed ABC-containing regimens 
at the time of the study, compared with 42% 
(413/995) of paediatric/adolescent patients 
(≤18 years). Among patients aged ≤18 years, 
11% (7/65), 54% (254/470), 33% (128/392) 
and 35% (24/68) were receiving ABC-
containing regimens at the central-, north-, 
west- and east-JHB clinics, respectively. At the 
west- and east-JHB clinics, nearly all patients 
receiving ABC (98%; 128/131 and 96%; 
24/25, respectively) were aged ≤18 years. The 
number of adults receiving ABC varied from 
2.3% (3/131) in west-JHB, to 4% (1/25) in 
east-JHB, 27% (95/349) in north-JHB and 94% 
(107/114) in central-JHB. Despite the small 
size of some cohorts, the results demonstrated 
a variation in the number of adults prescribed 
ABC at these 4 clinics.
Among paediatric and adolescent patients 
(aged ≤18 years), median time receiving ART 
and ABC varied by clinic. The TLC paediatric/
adolescent population had a median duration 
on ART of 91 months (IQR 40 - 94 months) 
compared with 37 months (IQR 24 - 51) at 
the north-JHB clinic and 6 months at both 
the west-JHB (IQR 3 - 27 months) and east-
JHB (IQR 2 - 8 months) clinics. A longer 
median duration of ART was associated with 
longer time receiving ABC, with paediatric/
adolescent patients at TLC prescribed the drug 
for a median 40 months (IQR 20 - 94 months). 
The median time on ABC was shorter at the 
north-JHB (13 months; IQR 6 - 24 months), 
west-JHB (5 months; IQR 2 - 8 months) and 
east-JHB clinics (5 months; IQR 2 - 6 months). 
More than half of the paediatric/adolescent 
patients at TLC (4/7; 57%) and the north-
JHB clinic (129/254; 51%) had been receiving 
ABC for longer than 12 months. Among adult 
patients receiving ABC at the clinics at the 
time of the study, 35% (TLC; 37/107) and 73% 
(north-JHB; 69/95) had been receiving the 
drug for longer than 1 year. Only 6% (8/128) 
of patients attending the west-JHB clinic were 
prescribed ABC for longer than 12 months.
The majority of adult patients prescribed 
ABC at the time of the study were switched 
onto the drug from other regimens, with only 
18% (19/107) of adult patients at TLC and 
28% (27/95) of adult patients at north-JHB 
clinic initiated on an ART regimen containing 
ABC. Among adult patients reporting a reason 
for switching to ABC from another regimen 
(52%; 81/156), the most common reasons were 
peripheral neuropathy (17%, 14/81), abnormal 
fat distribution (28%, 23/81) and toxicity (35%, 
28/81). Few specific reasons for switching to 
an ABC-containing regimen were given for 
paediatric/adolescent patients (25%, 62/247), 
but among those cases where a reason was 
reported, abnormal fat distribution was the 
leading cause of regimen change (76%, 47/62).
Discussion
When considering sites where both adults and 
children are routinely treated with ART, ABC 
is primarily prescribed to children. At the east- 
and west-JHB clinics, the drug was almost 
exclusively provided to patients aged ≤18 
years. We demonstrated a high variation in the 
prescription of ABC to adult and paediatric/
adolescent patients at the 4 sites across Gauteng 
Province. While we did not demonstrate 
dramatic over-use of the drug, 67% of patients 
receiving ABC were children, consistent with 
guidelines, while 33% were adults, as a likely 
result of being switched to ABC from another 
ART regimen due to adverse effects or toxicity. 
However, approximately 23% (46/202) 
of adults at central- and north-JHB were 
initiated on an ABC-containing regimen. A 
large proportion of ABC users at the north-
JHB clinic (73%; 254/349) were paediatric/
adolescent patients compared with a smaller 
proportion (27%; 95/349) of adults, yet still less 
than 2% (95/5 859) of patients aged ≥18 years 
were on an ABC-containing regimen. A large 
proportion of these adult patients receiving 
ABC reported long-term use of the drug 
(73% for 1 year or longer). The large number 
of adult patients receiving ABC at the north-
JHB clinic was likely related to being switched 
onto ABC from another ART regimen due to 
an adverse effect (i.e. peripheral neuropathy, 
lactic acidosis or lipoatrophy/lipodystrophy) – 
less than 30% of patients aged ≥18 years were 
initiated on an ABC-containing regimen.
The majority of paediatric/adolescent 
patients (<80%) at the north-JHB clinic were 
switched onto an ABC-containing regimen, 
with 19% (39/201) being due to abnormal fat 
redistribution. Once-daily use of ABC has 
been shown to be effective in older children, 
thereby facilitating adherence and improving 
patient satisfaction; and it is therefore possible 
that specialist paediatricians at north-JHB 
might have prescribed/switched adolescents 
to ABC for adherence issues.10,11 Twenty-one 
per cent of paediatric/adolescent patients were 
initiated on an ABC-containing regimen. A 
large proportion of these patients reported 
long-term use of the drug, with 51% (129/254) 
receiving ABC for longer than 1 year. This is 
likely due to the ageing paediatric population 
receiving care which has maintained paediatric 
regimens even after moving into adolescence 
(age 10 - 18 years).
Conversely, <1% (107/12 120) of adults at 
TLC were receiving ABC, only 35% (37/107) 
of whom had received the drug for longer than 
1 year. Adults were unlikely (17.8%; 19/107) 
to be initiated on an ABC-containing regimen 
but rather switched to such a regimen due to 
toxicity (82.2%; 88/107). The CD4 count (267 
cells/mm3; IQR 160 - 392) and proportion 
with a detectable viral load (13%; 10/80) at 
the initiation of ABC confirmed that adults 
patients were most likely switched to ABC 
rather than initiated on the drug. TLC treats 
few patients aged <18 years (0.5% of total 
patients); however, 71% (5/7) of paediatric/
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adolescent patients on an ABC-containing 
regimen were initiated on such a regimen.
Differences in ABC use across clinics 
possibly also partially reflect differences in 
clinical practice. More than 50% of children 
from the north-JHB clinic were receiving ABC 
for longer than 1 year, compared with 16% 
and 0% at west- and east-JHB, respectively. 
This could be a reflection of advice and 
recommendations concerning treating ART 
side-effects, from specialist paediatric HIV 
physician services available at north-JHB 
clinic (not available at the other sites). This 
advice might have included switching from 
stavudine- to ABC-containing regimens 
before implementation of the new national 
ART treatment guidelines. The switching of 
many children to ABC at north-JHB (79.1%; 
201/254) before implementation of the national 
guideline could explain the perception of high 
consumption of this drug in JHB.
The majority (79%) of children from the 
north-JHB clinic were switched onto ABC 
from another regimen, while 69% and 83% of 
children from west- and east-JHB, respectively, 
were initiated onto ABC. This likely reflects 
the implementation of the 2010 SA national 
ART treatment guidelines at these 2 sites, 
which recommend that infants and children be 
initiated on a regimen of ABC and lamivudine 
(3TC) plus lopinavir/ritonavir (LPV/r) or 
efavirenz (EFV).16 Among paediatric and 
adolescent patients, the most frequent reason 
for switching onto an ABC-containing regimen 
was ART toxicity and side-effects, most 
commonly abnormal fat redistribution. This 
highlights the toxicity of NRTIs, particularly 
d4T, didanosine (ddI) and zidovudine (AZT), 
even in children.7
The majority of adults prescribed ABC at the 
time of the study had been switched onto the 
drug from other regimens. Specified reasons 
for prescribing ABC to these adults were 
largely related to ART toxicity and side-effects, 
including renal toxicity, anaemia, peripheral 
neuropathy, abnormal fat distribution, and 
hyperlactataemia or lactic acidosis. This 
highlights the need to make ABC available 
to adults and include the drug in the national 
guidelines for adults as an alternative to 
standard first- and second-line ART.
Study strengths and 
limitations
The biggest strengths of this study include 
the size of the cohort and the depth of the 
data (using a standardised, electronic data-
capturing system, data on ART regimens, visit 
dates, outcomes, laboratory investigations and 
demographic data is of high quality).12 Since 
these are clinical cohorts, the findings should 
be considered in light of the study limitations 
which include missing data (laboratory 
investigations and reasons for switching) or 
under-reported conditions or adverse drug 
effects and the generalisability of the results. 
This study was done in RTC-supported sites 
in Johannesburg, thus with a higher level of 
clinical support and progressive prescription 
than other sites (i.e. rural sites without any 
supporting NGO). It is likely that ABC use, 
especially in adults, would be lower in rural, 
unsupported sites.
Conclusion
After reviewing the data, there did not appear 
to be a dramatic over-use of ABC (300 mg) in 
the 4 Gauteng sites. At the time of the study, 
there were 619 patients on ABC-containing 
regimens, accounting for only 2.7% of all 
the patients currently receiving ART at these 
clinics. Further, patterns of use at the 4 sites 
appeared in line with national ART treatment 
guidelines; most patients prescribed ABC were 
paediatric patients or adults experiencing drug 
toxicities on non-ABC-containing regimens.
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